SAGIMET BIOSCIENCES INC. - SERIES A COMMON STOCK

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

06 5月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

22 4月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

27 3月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

25 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

25 3月 2024 06:15:00 条件 Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

29 2月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

25 1月 2024 20:58:03 条件 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

23 1月 2024 17:45:51 条件 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

22 1月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

04 12月 2023 08:00:01 条件 Nasdaq GlobeNewswire